Mucinous ovarian cancer (MOC) is a rare subtype of epithelial ovarian carcinoma (EOC). The only possible risk factor correlated with MOC is tobacco smoking [9]. Most HGSCs present at an advanced stage, while MOC is diagnosed as stage 1 in 80% of the cases [10]. Prognosis is better in early disease, but worse in the advanced stage, compared to HGSC, which is due to insufficient response Faslodex manufacturer to platinum-based chemotherapy [11 primarily,12]. 2. Histogenesis Regular mucinous epithelium comprises three types of mucus-secreting cells, Faslodex manufacturer which range the abdomen (gastric), endocervix (endocervical), and intestine (intestinal). The standard ovarian tissues usually do not consist of the mucin-secreting cells. You can find multiple theories to describe the introduction of MOC: Adenoma carcinoma series stepwise style. The lifestyle of mucinous cystadenoma and mucinous borderline parts with carcinoma facilitates this theory. The carcinoma expands from harmless epithelium to borderline tumor to intrusive carcinoma. mutation happens early along the way, while TP53 mutation and HER2 amplification happen because they are specifically recognized in mucinous carcinoma [5 later on,13,14,15]. Germ cell source can be suggested by association with mature teratoma in 5% of instances and the common lifestyle of gastrointestinal-type cells, as well as the pancreatico-biliary and gastrointestinal markers. Nevertheless, most MOCs don’t have any teratomatous parts [3,16]. Mucinous metaplasia of the ovarian surface epithelium or within the lining of cortical inclusion cysts [3,16]. Strong association with endometriosis. They are usually endocervical-like or Mullerian mucinous tumors [3,16]. Mucinous epithelium frequently presents with Brenner tumors. Mucinous carcinoma, mainly the intestinal type, may evolve from transitional cells or metaplasia at the fallopian tube-peritoneal junction [3,16]. 3. Pathological Aspects Around 80% of mucinous carcinomas of the ovary are metastatic, with approximately 80% of primary tumors being stage I. The most frequent primary sites that metastasize to the ovary are: 45% from the gastrointestinal tract, 20% from the pancreas, 18% from the cervix and endometrium, and 8% from the breast [17,18]. It is agreed that diagnosing primary MOC requires careful pathological assessment as it is histologically very similar to other mucinous carcinomas, especially colorectal carcinoma (CRC). Recognizing the microscopic features and understanding the immunohistochemistry (IHC) profile of MOC are essential to reach a definitive diagnosis, which results in delivering proper treatment and an accurate prognosis. MOC is usually a heterogeneous tumor. It encompasses benign, borderline, and carcinoma components, which indicate a stepwise progression to carcinoma. The diagnosis of an invasive carcinoma requires the detection of stromal invasion of more than 5 mm or more than 10 mm2. Invasion less than these measurements is classified as micro-invasion with a borderline mucinous tumor. MOC is typically the intestinal type, but the endocervical type may develop infrequently [19,20,21]. According to the growth and invasion pattern, Lee and Schully classified MOC into expansile and infiltrative subtypes [22]. The expansile subtype has no destructive stromal invasion, but exhibits confluent or complex malignant glands (back to back glands) with or without minimal intervening stroma exceeding a 10 mm2 area or 3 mm each of two linear dimensions. The infiltrative type has stromal invasion in the form of glands, cell clusters, or individual cells, unsystematically Faslodex manufacturer infiltrating the stroma and often associated with a desmoplastic stromal reaction [20,21,22,23]. In 2014, the World Health Organization (WHO) adopted Lee and Schullys classification for MOC. Certain histological features are suggestive for metastatic mucinous carcinoma. In general, mucinous carcinomas are categorized into Rabbit polyclonal to ITIH2 cystic and colloid type, based on intracellular or extracellular mucin localization. Ovarian and pancreatic cystic mucinous carcinomas contain a large amount of intracellular mucin ( 50%) in at least 90% of tumor cells. On the other hand, colloid mucinous carcinomas arising from the gastrointestinal tract, lung, breast, and skin are associated with abundant extracellular mucin accounting for 50% or more tumor quantity [6]. Seidman et al. suggested an algorithm predicated on tumor size also to differentiate between MOC and metastatic mucinous carcinoma laterality. Tumors which were 10 cm and unilateral had been major MOCs 82% of that time period. Unilateral tumors 10 cm had been metastatic 87% of that time period. Bilateral tumors 10 cm had been metastatic in 92% of instances so when Faslodex manufacturer bilateral and 10 cm they.
Categories
- 11??-Hydroxysteroid Dehydrogenase
- 45
- 5-HT6 Receptors
- 7-TM Receptors
- 7-Transmembrane Receptors
- Acetylcholine Nicotinic Receptors, Non-selective
- Adrenergic ??1 Receptors
- Adrenergic Related Compounds
- AHR
- Aldosterone Receptors
- Androgen Receptors
- Antiprion
- AT2 Receptors
- ATPases/GTPases
- Atrial Natriuretic Peptide Receptors
- Calcineurin
- CAR
- Carboxypeptidase
- Casein Kinase 1
- Corticotropin-Releasing Factor
- CysLT1 Receptors
- Dardarin
- Deaminases
- Death Domain Receptor-Associated Adaptor Kinase
- Delta Opioid Receptors
- DMTs
- DNA-Dependent Protein Kinase
- Dual-Specificity Phosphatase
- Dynamin
- eNOS
- ER
- G Proteins (Small)
- GAL Receptors
- General
- GLT-1
- Glucagon and Related Receptors
- Glycine Receptors
- Growth Factor Receptors
- Growth Hormone Secretagog Receptor 1a
- GTPase
- Guanylyl Cyclase
- KDM
- Kinesin
- Lipid Metabolism
- Main
- MAPK
- MCH Receptors
- Muscarinic (M2) Receptors
- NaV Channels
- Neurotransmitter Transporters
- NFE2L2
- Nitric Oxide Precursors
- Nitric Oxide Signaling
- NPFF Receptors
- Opioid
- Other
- Other MAPK
- Other Peptide Receptors
- Other Transferases
- OX1 Receptors
- OX2 Receptors
- OXE Receptors
- PAO
- Phosphatases
- Phosphoinositide 3-Kinase
- Phosphorylases
- Pim Kinase
- Polymerases
- Purine Transporters
- Sec7
- Serine Protease
- Sodium/Calcium Exchanger
- Sphingosine Kinase
- V2 Receptors
-
Recent Posts
- [PubMed] [Google Scholar] 52
- Methods and Material 2
- It has been well established that harboring the allele enhances dementia associated with Alzheimers disease (AD), and several studies have supported a role of proteolysis as an important factor that may contribute to this risk [2,3C10]
- [PubMed] [Google Scholar]Xiao YF, Ke Q, Wang SY, Auktor K, Yang Con, Wang GK, Morgan JP, Leaf A
- Although passively-administered hyperimmune serum conferred protection in intact birds [15,17,18], the contribution of innate defenses and cell-mediated immunity to the control of APEC in the avian host remains ill-defined
Tags
- 68521-88-0
- a 105-120 kDa heavily O-glycosylated transmembrane glycoprotein expressed on hematopoietic progenitor cells
- Ankrd11
- Capn1
- Carboplatin cost
- DKFZp781B0869
- HA6116
- Hdac11
- IGF2R
- INK 128 supplier
- JTK4
- LRP2
- Masitinib manufacturer
- MDA1
- Mouse monoclonal to CD34.D34 reacts with CD34 molecule
- Mouse monoclonal to ERBB3
- Mouse monoclonal to INHA
- order NVP-AEW541
- PECAM1
- Rabbit Polyclonal to AML1
- Rabbit polyclonal to AML1.Core binding factor CBF) is a heterodimeric transcription factor that binds to the core element of many enhancers and promoters.
- Rabbit Polyclonal to AQP12
- Rabbit Polyclonal to C-RAF phospho-Ser301)
- Rabbit Polyclonal to C-RAF phospho-Thr269)
- Rabbit polyclonal to CD80
- Rabbit Polyclonal to Claudin 3 phospho-Tyr219)
- Rabbit Polyclonal to CYSLTR1
- Rabbit polyclonal to DDX20
- Rabbit Polyclonal to EDG4
- Rabbit Polyclonal to FGFR2
- Rabbit Polyclonal to GAS1
- Rabbit Polyclonal to GRP94
- Rabbit polyclonal to INMT
- Rabbit Polyclonal to KAPCB
- Rabbit Polyclonal to MMP-2
- Rabbit Polyclonal to MT-ND5
- Rabbit Polyclonal to OR52E2
- Rabbit polyclonal to PHC2
- Rabbit Polyclonal to RAB31
- Rabbit Polyclonal to SLC25A31
- Rabbit Polyclonal to ZC3H13
- Rabbit polyclonal to ZNF268
- TNFRSF13C
- VAV1
- Vegfa